IP Library Granted Patent US 10,894,012
Granted Patent B1
US 10,894,012 · App. 16/903,558 · Granted Jan 19, 2021

Pharmaceutical compositions and methods of using the same

Inventors: Jeffrey M. Moshal (Allentown, PA); Michael Libman (Allentown, PA)
Assignee: GENUS LIFESCIENCES INC.
A61K9/0043A61B17/24A61K31/46A61M19/00A61P23/02A61B1/233A61B2017/246
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,894,012
App. No.
16/903,558
Granted
Jan 19, 2021
Kind
B1
Abstract

Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.

Claims (23)

1. A method of providing induction of local anesthesia of mucous membranes in an adult patient comprising:

soaking four pledgets in about 4 mL of a pharmaceutical composition comprising about 36 mg/mL to about 44 mg/mL of cocaine hydrochloride, 1.2 mg/mL to 1.4 mg/mL citric acid, 0.7 mg/mL to 1.3 mg/mL sodium benzoate, and water;

placing a maximum of two pledgets of the four pledgets in each nasal cavity of an adult patient for about 10 minutes to about 20 minutes, provided that the method results in an AUC inf in a range from about 25.0 ng*h/mL to about 370 ng*h/mL of cocaine in the adult patient; and

performing a diagnostic or surgical procedure on or through the nasal cavities in the adult patient;

provided that the method results in a reduction in pain equivalent to achieving a visual numeric rating score of 0 upon von Frey filament testing.

2. The method of claim 1 , wherein the procedure is a nasal laryngoscopy.

3. The method of claim 1 , wherein the procedure is a nasopharyngeal laryngoscopy.

4. The method of claim 1 , wherein the procedure is a nasal endoscopy.

5. The method of claim 1 , wherein a length of each of the four pledgets is about 3.0 cm.

6. The method of claim 1 , wherein each of the four pledgets has an absorbency sufficient to absorb about 1 mL of the pharmaceutical composition.

7. The method of claim 1 , wherein each of the four pledgets is removed from the nasal cavity and retains between about 70% and about 80% of the pharmaceutical composition.

8. A method of providing induction of local anesthesia of mucous membranes in an adult patient comprising:

soaking four pledgets in about 4 mL of a pharmaceutical composition comprising about 36 mg/mL to about 44 mg/mL of cocaine hydrochloride, 1.2 mg/mL to 1.4 mg/mL citric acid, 0.7 mg/mL to 1.3 mg/mL sodium benzoate, and water;

placing a maximum of two pledgets of the four pledgets in each nasal cavity of the adult patient for about 10 minutes to about 20 minutes, provided that the method results in an AUC inf in a range from about 25.0 ng*h/mL to about 370 ng*h/mL of cocaine in the adult patient;

provided that the method results in a T max ranging from about 0.02 hours to about 1.00 hours; and

performing a diagnostic or surgical procedure on or through the nasal cavities in the adult patient;

provided that the method results in a reduction in pain equivalent to achieving a visual numeric rating score of 0 upon von Frey filament testing.

9. The method of claim 8 , wherein the procedure is a nasal laryngoscopy.

10. The method of claim 8 , wherein the procedure is a nasopharyngeal laryngoscopy.

11. The method of claim 8 , wherein the procedure is a nasal endoscopy.

12. The method of claim 8 , wherein a length of each of the four pledgets is about 3.0 cm.

13. The method of claim 8 , wherein each of the four pledgets has an absorbency sufficient to absorb about 1 mL of the pharmaceutical composition.

14. The method of claim 8 , wherein each of the four pledgets is removed from the nasal cavity and retains between about 70% and about 80% of the pharmaceutical composition.

Assignments (4)
SECURITY INTEREST Recorded Apr 27, 2026
From: LXO IRELAND DESIGNATED ACTIVITY COMPANY
To: KROLL TRUSTEE SERVICES LIMITED, AS SECURITY AGENT
Reel/Frame 074483/0163 →
CHANGE OF NAME Recorded Dec 10, 2025
From: NODEN PHARMA DESIGNATED ACTIVITY COMPANY
To: LXO IRELAND DESIGNATED ACTIVITY COMPANY
Reel/Frame 073940/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2023
From: GENUS LIFESCIENCES INC.
To: NODEN PHARMA DESIGNATED ACTIVITY COMPANY
Reel/Frame 062999/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: MOSHAL, JEFFREY M.; LIBMAN, MICHAEL
To: GENUS LIFESCIENCES INC.
Reel/Frame 053485/0239 →
Continuity (4)
Continuation 16510516 · Jul 12, 2019
Continuation 15934562 · Mar 23, 2018
Continuation In Part 15434014 · Feb 15, 2017
Continuation In Part 15427011 · Feb 7, 2017
Cited By (1)
US 12,508,256